for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

GlaxoSmithKline Pharmaceuticals Limited

GLAX.NS

Latest Trade

1,535.00INR

Change

-3.10(-0.20%)

Volume

4,738

Today's Range

1,526.90

 - 

1,549.55

52 Week Range

962.65

 - 

1,807.50

As of on the National Stock Exchange of India ∙ Minimum 15 minute delay

Pricing

Previous Close
1,538.10
Open
1,538.15
Volume
4,738
3M AVG Volume
2.56
Today's High
1,549.55
Today's Low
1,526.90
52 Week High
1,807.50
52 Week Low
962.65
Shares Out (MIL)
169.41
Market Cap (MIL)
257,192.20
Forward P/E
--
Dividend (Yield %)
1.32

Next Event

GlaxoSmithKline Pharmaceuticals Ltd Annual Shareholders Meeting

Latest Developments

More

GlaxoSmithKline Pharmaceuticals Says Profitability Of Q1FY21 May Be Impacted Due To COVID-19

Glaxosmithkline Pharmaceuticals To Discontinue Supply Of Ranitidine Products

Glaxosmithkline Pharmaceuticals March Qtr Profit Falls

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About GlaxoSmithKline Pharmaceuticals Limited

GlaxoSmithKline Pharmaceuticals Limited is a pharmaceutical company. The Company and its subsidiary are engaged in the business of manufacturing, distributing and trading in pharmaceuticals. The Company develops a range of products in approximately three areas, including pharmaceuticals, vaccines and consumer healthcare. The Company's product portfolio includes prescription medicines and vaccines. The Company's prescription medicines range across therapeutic areas, and it also offers a range of vaccines for prevention of life-threatening diseases, such as pneumococcal disease, meningitis, hepatitis, rotavirus, whooping cough, small pox and influenza. It provides healthcare solutions to patients, with a range of prescription medicines across areas covering anti-infectives, dermatology, gynecology, diabetes, oncology, cardiovascular disease and respiratory diseases. The Company's manufacturing unit is located at Nashik, and its clinical development center is located in Bangalore.

Industry

Biotechnology & Drugs

Contact Info

Dr Annie Besant Road, Worli

400030

India

+91.22.24959595

http://india-pharma.gsk.com/

Executive Leadership

Deepak S. Parekh

Non-Executive Chairman of the Board

Puja Thakur

Chief Financial Officer, Whole Time Director

D. Bartaria

Executive Vice President– Pharmaceuticals

H. Buch

Executive Vice President - Pharmaceuticals

Ajay A. Nadkarni

Compliance Officer, Company Secretary, General Manager - Administration

Key Stats

2.57 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, INR)

2018

28.7K

2019

31.3K

2020

31.9K

2021(E)

33.5K
EPS (INR)

2018

19.655

2019

24.600

2020

26.700

2021(E)

30.694
Price To Earnings (TTM)
239.95
Price To Sales (TTM)
8.34
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
133.40
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

BRIEF-GlaxoSmithKline Pharmaceuticals Says Profitability Of Q1FY21 May Be Impacted Due To COVID-19

* CURRENTLY OPERATING AT ABOUT 70% OF NORMATIVE MANUFACTURING LEVELS

BRIEF-Glaxosmithkline Pharmaceuticals To Discontinue Supply Of Ranitidine Products

* WILL REQUEST CANCELLATION OF MARKETING AUTHORIZATION(S) ASSOCIATED WITH ZINETAC Source text for Eikon: Further company coverage:

BRIEF-Glaxosmithkline Pharmaceuticals March Qtr Profit Falls

* MARCH QUARTER CONSOL PROFIT 1.38 BILLION RUPEES VERSUS 1.47 BILLION RUPEES YEAR AGO

BRIEF-Glaxosmithkline Pharmaceuticals Appoints Sridhar Venkatesh As Managing Director

* GLAXOSMITHKLINE PHARMACEUTICALS LTD SAYS APPOINTED SRIDHAR VENKATESH AS MANAGING DIRECTOR OF COMPANY EFFECTIVE 1ST APRIL, 2020

BRIEF-India's Glaxosmithkline Pharmaceuticals Dec Qtr Profit Rises

* DEC QUARTER PROFIT 896.9 MILLION RUPEES VERSUS PROFIT 529.5 MILLION RUPEES YEAR AGO

BRIEF-Glaxosmithkline Pharmaceuticals ‍appoints Puja Thakur as CFO​

* Says appointed Puja Thakur as whole-time director and CFO Source text: http://bit.ly/2gDubM1 Further company coverage:

BRIEF-India's Glaxosmithkline Pharmaceuticals Sept-qtr profit up 32 pct

* Sept quarter profit 1.30 billion rupees versus profit of 988.5 million rupees last year

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up